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Abstract
Substance use complicates HIV care and prevention. Primary care clinics are 
an ideal setting to screen for and offer interventions for unhealthy alcohol 
and drug use; however, few HIV clinics routinely screen for substance use. 
We enrolled 208 clinic patients at an urban underserved HIV primary care 
clinic and screened for substance use with the Alcohol, Smoking, and 
Substance Involvement Score Test (ASSIST) and measured urine toxicology. 
Of the 168 participants who completed screening, the majority reported 
tobacco or non-prescribed substance use in the previous 3 months. White 
men reported significantly more amphetamine-type stimulant use compared 
to African American and Latino men (p < 0.001). Implementing standard 
clinic practice for screening and assessing substance use in HIV primary care
clinics is needed.
Keywords: gender, HIV, SBIRT, substance use
Clinical settings offer an opportunity to address substance use 
(including alcohol, tobacco, and illicit drugs) in persons living with HIV 
(PLWH). Substance use in PLWH is associated with HIV transmission risk 
behavior, low antiretroviral therapy (ART) adherence, HIV progression, 
detectable viral load, and poorer perceived quality of life (Walter & Petry, 
2015). Not all substance use that PLWH engage in constitutes an alcohol or 
substance use disorder; nonetheless, PLWH have reported experiencing 
physical, social, and psychological harmful effects of substance use. In 
addition, studies have reported the harms of alcohol, tobacco, and illicit 
substance use in this population (Gonzalez, Barinas, & O'Cleirigh, 2011). In 
the general population as well as in PLWH, the consequences of 
unrecognized and untreated substance use are clinically, socially, and 
economically significant. The U.S. Public Health Service has endorsed routine
and universal alcohol and tobacco screening in primary care (U.S. Preventive
Services Task Force, 2004 ); however, few HIV primary care clinics routinely 
assess patients for alcohol or other substance use (Surah et al., 2013).
The effects of alcohol, tobacco, and illicit substance use take a greater 
combined toll on the health and wellbeing of Americans than any other 
preventable factor. Alcohol and tobacco use are significant risk factors for 
cardiovascular disease and cancer, which are the leading causes of death 
(O'Keefe, Bhatti, Bajwa, DiNicolantonio, & Lavie, 2014). In a national survey 
on substance use (alcohol and illicit drugs) and health, more than 71% of 
U.S. adults reported alcohol use in the previous year (Substance Abuse and 
Mental Health Services Administration, 2014). In 2007, substance use 
contributed to more than half of suicides and violent crimes in the United 
States (Sacks et al., 2009). The economic cost of the global burden of 
disease and health care utilization that are attributable to alcohol use are 
immense (Rehm et al., 2010).
Alcohol, tobacco, and illicit drug use can complicate HIV health care 
and health outcomes by interfering with medication access and adherence, 
contributing to HIV pathogenesis, increasing transmission risk behaviors, and
destabilizing sources of social and financial support. PLWH who use 
substances are less likely to be prescribed ART and those on ART have 
shown reduced ART adherence (Golin et al., 2002; Volkow & Montaner, 
2010). Studies that have enrolled active substance users show mixed results 
on HIV medication adherence. Historically, studies with PLWH who reported 
illicit drug use while on ART had poorer health outcomes than those who did 
not use drugs, (Arnsten et al., 2007) while more current studies among PLWH
who inject drugs and are on HIV treatment show survival rates that are 
similar when comparing people who inject drugs with those who do not 
(Spiller et al., 2015). In addition to complicating treatment and HIV 
outcomes, research has also shown an association between active substance
use (alcohol and illicit drugs) and high-risk HIV transmission behaviors, 
including unprotected anal and vaginal intercourse with uninfected partners 
(Kalichman et al., 2009).
Stimulant use by PLWH is also a critical factor in HIV health outcomes. 
Cocaine use has been shown to enhance viral replication and quiescent T-cell
permissiveness to HIV infection, increasing the viral reservoir; cocaine is also
an independent factor for unsuppressed viral load and increased 
neurocognitive disorders (Kim et al., 2015). Methamphetamine use has been 
associated with primary drug resistance to non-nucleoside reverse 
transcriptase inhibitors, increased cognitive decline, inflammation in the 
brain, and ischemic events (Cattie et al., 2014). Methamphetamine use also 
doubles or triples the probability of engaging in high-risk sexual behavior and
acquisition of sexually transmitted infections (STIs) including HIV (Colfax & 
Shoptaw, 2005). HIV infection is more likely among women who use crack 
cocaine than women who don’t, and suicide attempts for PLWH are more 
prevalent in persons who use drugs (Walter & Petry, 2015) and are related to
poorer emotional and cognitive quality of life measures. Several studies have
now demonstrated the relationship between substance use and HIV 
acquisition and increased morbidity and mortality for PLWH (Kuo et al., 
2014).
Screening for substance use and identifying those with risky alcohol 
and drug use behaviors in primary care settings allows for an integrated 
approach to respond to harmful substance use. As with many chronic 
diseases, screening and early detection can serve as a form of preventive 
care (Saitz et al., 2010) as well as to identify patients where further clinical 
intervention may be warranted. A study of alcohol and drug use screening is 
especially relevant in HIV clinical settings, where substance use is 
widespread (Mimiaga et al., 2015). HIV care providers have the opportunity 
to identify and intervene with patients who otherwise would be unlikely to 
access specialty treatment for substance use. Screening and assessment for 
unhealthy substance use offers clinicians the opportunity to identify harmful 
substance use or disorders and provides the opportunity to address such 
use. However, few studies have reported on screening for substance use as 
part of HIV primary care. The goal of our study was to characterize patterns 
and severity of substance use through two different screening and 
assessment approaches in a large, urban public HIV clinic providing primary 
care to PLWH and to describe gender and racial differences in alcohol, 
tobacco, and other substance use. 
Methods
Design: Sample, Setting, and Data Collection
Patients (N = 208) were recruited and enrolled in a parent Screening, 
Brief Intervention, and Referral to Treatment (SBIRT) trial (Dawson Rose et 
al., 2015). Potential subjects were recruited from a convenience sample of 
patients receiving HIV primary care at the UCSF Positive Health Program 
(PHP) clinic at San Francisco General Hospital. The PHP clinic is one of the 
oldest and largest HIV clinics in the United States, providing primary medical 
care to more than 2,500 HIV-infected patients annually. All study protocols 
were reviewed and approved by the University of California San Francisco 
Institutional Review Board and the clinical site.
Study eligibility included: 18 years of age or older, confirmed HIV-
infected serostatus, ability to provide informed consent to be a research 
participant and to be followed over a 6-month period, ability to speak English
or Spanish, and receiving HIV care at the PHP clinic. We also asked study 
participants for their written consent to abstract biological measures from 
their electronic health records. Study materials were provided in both English
and Spanish.
Study participants completed a self-administered survey upon 
enrollment to the study. They were asked to submit a urine specimen for 
drug toxicology screening, although this was not a requirement for study 
participation. Study participants included in our sub-analysis completed both 
screening measures. Participants received $35 for completing each study 
visit and an additional $10 for urine samples provided. 
Measures
Demographics. Participants completed a demographic questionnaire 
that we have used in multiple studies with PLWH. The questionnaire asked 
about age, gender, race, adequacy of income, education, and year of HIV 
diagnosis (Tyer-Viola et al., 2014). 
Substance use screening tools. We used two substance use screening 
measures in this analysis: the Alcohol, Smoking and Substance Involvement 
Screening Test (ASSIST; World Health Organization [WHO] ASSIST Working 
Group, 2002) which is a validated screening tool for unhealthy use and the 
Sure-Screen® urine toxicology test. The ASSIST is a low-cost, self-report, 8-
item screening questionnaire developed for use in primary care settings to 
screen for the presence of alcohol and other substance use disorders 
(Humeniuk et al., 2008; WHO ASSIST Working Group, 2002). ASSIST collects 
information about lifetime non-medical substance use, previous 3-month 
substance use, frequency of use, cravings, and problems related to 
substance use – including health, social, legal, or financial problems; failing 
to do what was normally expected because of drug use; having someone 
express concern about a person’s drug use; trying and failing to control, cut 
down, or stop using; risk of current or future harm; level of dependence; and 
injection drug use. The responses are summed to provide both a continuous 
Specific Substance Involvement Score (SSIS) and validated cut points for 
each substance that translate to low, moderate, or high risk use, which 
indexes the risk for each substance assessed. A moderate SSIS risk score 
indicates individuals who should be offered a brief intervention or a referral 
for substance use treatment. A high-risk score indicates a need for more 
intensive treatment or attention to the substance being used at high-risk 
levels.
Urine specimens were collected and screened using the 8-panel Sure-
Screen® (MEDTOX Scientific, 2015), a rapid qualitative immunoassay 
screening test for detection of multiple drugs and drug metabolites in human
urine. The Medtox 11-panel Sure-Screen® tests for eleven substances at the 
following cut-off concentrations:  amphetamine (d-amphetamine) 300 ng/mL,
barbiturates (butalbital) 200 ng/mL, benzodiazepines (nordiazepam) 200 ng/
mL, cocaine (benzoylecgonine) 100 ng/mL, methamphetamine (d-
methamphetamine) 1000 ng/mL, methadone (methadone) 200 ng/mL, 
opiates (morphine) 100 ng/mL, oxycodone 100 ng/mL, phencyclidine 
(phencyclidine) 25 ng/mL, propoxyphene (norpropoxyphene) 300 ng/mL, and
cannabinoids (11-nor-9-carboxy-Ä9-THC) 40 ng/mL.  Confirmatory testing of 
positive immunoassay results gas chromatography/mass spectrometry or 
liquid chromatography/tandem mass spectrometry was not conducted.
Clinical measures. CD4+ T cell count and HIV viral load (VL) 
measurements were extracted from electronic medical records in the 
hospital database. Using the date of the participants’ study visit, the most 
recent CD4+ T cell count and VL measures in the electronic medical record 
were retrieved. The clinical site where these data were collected measured 
VL with the RealTime™ HIV-1 VL assay, which has a lower limit of detection 
of 70 HIV RNA copies/mL (Arredondo et al., 2012). 
Data Analysis
 Descriptive statistics, including frequencies, percentages, means, and 
standard deviations were performed to characterize the sample. Pearson’s 
chi-square and Fischer’s exact test analyses were used to determine 
differences in risk stratification of SSIS scores between male and female 
genders, and across the four race/ethnicity categories (African American, 
Hispanic or Latino/a, White/Anglo, and Other) and substances detected via 
urine toxicology. All analyses were conducted with STATA 14. Urine 
toxicology screens provides information that will tell you if a substance is 
present in the urine or not, however, urine tests cannot be used for diagnosis
of a substance use disorder. 
Results
Sample Characteristics
We enrolled 208 HIV primary care clinic patients from an urban public 
clinic. The analysis presented here is based on the 168 participants who 
completed both the ASSIST questionnaire and urine drug screening 
procedure. The participants were primarily male (68.4%); and more than one
third (40.5%) were African American (Table 1). There were no significant 
demographic differences between the entire sample of 208 and the analytic 
sample of 168. The average age was 45.66 years (SD = 8.45) with an 
average of 12.40 years living with HIV. The majority (67.2%) of the 
participants had an undetectable HIV viral load (≤ 75copies/mL). 
Alcohol and Substance Use
More than two thirds of the study sample reported using tobacco or 
other non-prescribed substances in the previous 3 months. Forty-one percent
of our participants (n = 65) reported alcohol use for the same time period. As
described in the Methods section, we determined Single Substance 
Involvement Scores (SSIS) for each substance reported and stratified these 
scores into low (0-3), moderate (4-26), and high risk (27+) for all substances 
except alcohol (low risk = 0-10, moderate risk = 11-26, high risk = 27+), 
following the validated ASSIST scoring guidelines. More than half of our 
participants’ SSIS scores indicated moderate risk for tobacco, (n = 91, 
54.2%) and cannabis (n = 88, 52.4%; Table 2). The three drug classes with 
the greatest number of participants exhibiting high-risk scores were for 
tobacco (n = 30, 17.8%), cocaine (n = 20, 11.9%), and amphetamine (n = 
18, 10.7%). The SSIS for alcohol use indicated that over one-third of study 
participants (n = 52) reported a moderate risk level for alcohol and 7.7% (n 
= 13) had a high-risk score for alcohol use. 
When comparing the SSIS score for each substance by gender and 
race, we observed differences in reported substance use. Compared to 
females, males in this sample reported greater levels of moderate risk 
cannabis use (p = 0.03) and moderate risk amphetamine use (p < 0.001). 
There were also significant differences for cocaine use with Hispanic or 
Latino/a participants reporting lower risk use than African American, 
White/Anglo, or Other race participants (p = 0.04). Finally, more African 
American participants reported low or no risk amphetamine use as compared
to Hispanic or Latino/a, White/Anglo, or Other race participants (p < 0.001). 
More than half of the sample submitted urine specimens that tested 
positive for cannabis (52.4%), nearly one third (28.6%) tested positive for 
cocaine, and almost a quarter (24.4%) tested positive for benzodiazepines. 
Significant gender differences in urine toxicology were also present (Table 3).
Male gender was significantly associated with positive urine toxicology for 
amphetamine (20.0%, p < 0.001) and methamphetamine (25.2, p < 0.001). 
Female gender was significantly associated with positive urine toxicology for 
cocaine (39.6%, p = 0.03), methadone (30.2%, p < 0.001), and opiates 
(28.3%, p = 0.04). Significant racial differences were also observed in urine 
toxicology. Those of Other race or ethnicity screened positive for cannabis 
use more frequently (77.8%, p = 0.02). Both Hispanic or Latino/a participants
and White/Anglo participants screened positive for cocaine (18.5% and 
16.4% respectively, p < 0.001) less frequently. African American race or 
ethnicity was associated with lower levels of positive urine toxicology for 
both amphetamine (5.9%, p = 0.03) and methamphetamine (7.5%, p = 
0.01). 
Discussion
In this study of patients in an HIV primary care clinic-based urban 
population, we found high rates of self-reported substance use, which were 
confirmed by urine toxicology testing. The SSIS risk scores for all substances,
excepting inhalants and hallucinogens, demonstrated that moderate and 
high-risk substance use was highly prevalent in this sample of patients. 
Reported substance use in this HIV clinic sample was higher than in other 
studies of both HIV and non-HIV primary care patient samples for most 
substances reported except for tobacco use. In the United States, 
approximately 19% of the adult population smokes cigarettes (Centers for 
Disease & Prevention, 2012). When compared to the U.S. general population,
a number of studies have documented considerably higher rates of smoking 
in PLWH (Lifson & Lando, 2012), which is of grave concern given the now 
well-documented increased mortality associated with smoking among PLWH 
due to cardiovascular disease and non-AIDS related cancers (Helleberg et al.,
2015; Rasmussen et al., 2015). For other substances such as cannabis, our 
sample exhibited levels of use similar to other primary care settings (Saitz et
al., 2014) where the ASSIST measure was used. However, in another study of
an HIV clinic-based sample, the reported use of cannabis was 18% (Skalski et
al., 2015), which was considerably lower than what we found in our study. 
When examining other substances reported by participants in our 
study, we saw similarities compared to other clinic samples of HIV-infected 
and uninfected patients, for example with stimulant use (cocaine, crack 
cocaine, methamphetamines; Bing et al., 2001; Cook et al., 2008). A large 
number of participants in our sample reported moderate or higher ASSIST 
scores for cocaine (51.2%) and amphetamine-type stimulants (44.6%). There
have been a multitude of studies on stimulant use and HIV, ranging from 
stimulants as a risk factor for HIV transmission and as a method of managing
mental health symptoms and the experience of discrimination, to the 
manner in which they impacted adherence to ART; however, very few of 
these samples were drawn solely from clinic settings where HIV care was 
delivered. In the studies that have been conducted in HIV primary care 
settings, a range of stimulant use has been reported. Skeer et al. (2012) 
studied HIV-infected men who have sex with men (MSM) in a large primary 
care setting in Boston, MA. and reported that 21% of their sample used 
amphetamines. In an earlier study (Bing et al., 2001) of a nationally 
representative probability sample of PLWH, 40% of the subjects reported 
using an illicit drug other than cannabis. In a more recent study of the 
Women’s Interagency HIV Study, investigators did not solely recruit samples 
from HIV primary clinics; however, nearly one third (28.6%) of the HIV-
infected women in the sample reported crack cocaine use within the 
previous 3 months (Cook et al., 2008). 
The participants in our study also reported a high prevalence of 
moderate-severe SSIS for alcohol (41%). In comparison, the 2013 National 
Survey on Drug Use and Health determined the national rate of alcohol use 
disorders was 7% (Substance Abuse and Mental Health Services 
Administration, 2014). While in studies conducted in general outpatient 
settings site the prevalence of unhealthy alcohol use ranging from 7 and 
20% (Saitz, 2005). The methods used in these studies vary, however, the 
prevalence of alcohol use in general medical settings is much lower than 
what we measured in this sample. Alcohol like other substance use can 
complicate HIV care and treatment outcomes and continues to be a major 
driver of HIV acquisition.  
Substance use patterns can differ between women and men. In the 
literature, many studies of HIV and substance use conducted with MSM have 
focused on alcohol or amphetamine use (Stahlman, Javanbakht, Stirland, 
Guerry, & Gorbach, 2013), while studies of HIV-infected women have been 
more focused on crack cocaine and heroin use (Cook et al., 2008).  In our 
study, we observed gender differences in SSIS scores and in urine toxicology 
results. Males in our sample had a significantly higher proportion of 
moderate or high-risk SSIS scores for amphetamine (p < 0.001) and for 
cannabis (p = 0.02; Table 2), while women had significantly higher levels of 
cocaine, methadone, and opiate positive urines when compared to men (p = 
0.03). This differed from what we observed in the self-report SSIS scores. 
While women were marginally more likely than men to report moderate or 
high-risk cocaine use, this difference was not statistically significant. Many 
studies in the HIV literature have focused on men, MSM, or women and 
substance use. To our knowledge, however, no studies analyzed gender 
differences between men and women in an HIV-infected sample. One more 
general study found that women were more likely to have a substance use 
disorder combined with other mental illness compared to men; however, 
there were no gender differences in the presence of a substance use 
disorder in the absence of mental illness (Fries, Fedock, & Kubiak, 2014). 
Urine toxicology in our study looked different from self-report 
responses using the ASSIST. Urine drug screening is limited (with few 
exceptions) to the detection of drug use within a few days before the test 
and, as in most tests, false positives and false negatives as well as technical 
problems can occur. Although objective, the use of biomarkers is not without 
limitation. The literature has indicated that, in some persons who use drugs, 
self-report, when compared to urine toxicology verifies under reporting of 
illicit substance use, although it is not known how widespread this is. Also, 
some clinicians may conduct urine screening as evidence of therapeutic 
adherence and evidence of use or non-use of illicit drugs. . In our sample, 
women had more methadone and opiates in their urine when compared with 
men; however, opiates and methadone are both commonly prescribed in 
medical settings for both pain management and opiate agonist therapy 
(Nosyk et al., 2014) and we did not systematically ask participants if they 
were being prescribed opiates.  As reported by Robinson-Papp, Elliott, 
Simpson, and Morgello (2012), singular reliance on self-reports for 
implementation of substance use screening and brief interventions has 
limitations. In addition, more stigmatized drugs, such as cocaine, 
methamphetamine, or heroin, may be under-reported using self-report but 
could be documented with urine toxicology tests (Decker et al., 2014). In this
study participants were paid for urine testing which might not happen in a 
primary care setting so motivation to provide a urine sample may be 
different.  While we are not advocating urine screening as the initial step for 
screening in a clinical setting, some clinicians may use it as a tool to work 
with patients with a history of substance use to validate their reported use 
and not as a test, which could penalize the patient (Pellico, Gilliam, Lee, & 
Kerns, 2014). Although substance use levels differed by screening modality 
in our study, the evidence clearly pointed to high levels of substance use in 
this HIV clinic sample.
High amounts of reported substance use found in our study and others 
highlights a critical problem that HIV clinicians may be overlooking and that 
could be addressed by universal substance use screening. Based on the 
evidence of efficacy for screening and offering a brief intervention for alcohol
and tobacco use, the U.S. Preventive Services Task Force (2004) has 
recommended universal preventive substance use screening in primary care 
for adolescents and adults (Saitz et al., 2010). While screening and brief 
intervention has shown promise for harmful alcohol use and smoking 
(Pilowsky & Wu, 2012), the efficacy of universal BI for illicit drug use and 
prescription drug misuse has not been universally recommended for primary 
care settings (Saitz et al., 2014). However, because of the overwhelming 
evidence that illicit drug use negatively impacts health, research to 
determine the efficacy of screening and brief intervention for drug use is 
ongoing.
SBIRT has emerged as an important model for identifying and 
addressing substance use problems in health care settings (Madras et al., 
2009). Brief intervention approaches are typically delivered on site, and 
individuals with more severe substance use problems also may be offered 
referrals to specialized treatment. Brief intervention for non-treatment-
seeking samples has strong support in the alcohol literature (Cuijpers, Riper, 
& Lemmers, 2004; Kaner et al., 2009) and some promising effects have been
observed with respect to other substance use (Humeniuk et al., 2012; 
Ondersma, Svikis, & Schuster, 2007). Substance use screening followed by a 
brief intervention conducted by an individual trained in motivational 
interviewing has been extensively examined in adolescents and young adults
using drugs and alcohol. These studies have revealed significant reductions 
in marijuana use (Saitz et al., 2014); decreases in alcohol use, binge 
drinking, and days of drug use (Winters & Leitten, 2007); lower alcohol, 
tobacco, and cannabis use (McCambridge & Strang, 2005); and reductions in 
illicit drug use (Peterson, Baer, Wells, Ginzler, & Garrett, 2006). 
To our knowledge, few studies of SBIRT have been conducted in HIV 
settings. Cropsey et al. (2013) conducted an SBIRT feasibility and 
acceptability study in an HIV primary care clinic to address the high rates of 
smoking by PLWH; the findings of Cropsey’s study indicated that SBIRT was 
feasible and acceptable to staff and patients in the HIV primary care setting. 
Using SBIRT as an approach for SBI was feasible and acceptable for many 
participants in our study (Dawson Rose et al., 2015). SBIRT has been 
implemented in HIV settings in the state of Colorado and results are 
forthcoming (Fischer, 2012). Given the amount of substance use in PLWH 
and its impact on HIV care engagement (O'Cleirigh, Magidson, Skeer, Mayer, 
& Safren, 2014); screening and brief intervention in HIV care settings could 
be a critical component of the HIV care coordination. More investigation is 
needed to determine how to best implement substance use screening and 
brief intervention within the workflows of primary care HIV clinics. 
Study Limitations
Our sample was recruited from the clinic waiting room and thus 
represents patients that are engaged in care and may not be representative 
of the entire clinic.  The most current patient demographic data for the clinic 
indicated that most were male (84.0%) and racially diverse with nearly half 
(48.3%) Caucasian, 24.4%, African American, and 22.6% Hispanic or 
Latino/a. The demographic report by the clinic also indicated that the HIV 
exposure category was primarily MSM (66.0%) but also included 
heterosexual exposure (25.8%) and injection drug use (23.4%). Our study did
not collect data on HIV exposure category. Our efforts to oversample women 
and people of color were successful as demonstrated by our participants, 
who were 31% women and 68% people of color, both populations that are 
often underrepresented. In addition, the high mean CD4+ T cell count and 
high level of viral suppression in our cohort while typical of this clinic and 
San Francisco on the whole, was atypical when compared to Gardner’s 
cascade (Gardner, McLees, Steiner, Del Rio, & Burman, 2011), and may have
indicated that, despite the prevalence of substance use in our sample, the 
participants were able to control their use well enough to remain adherent to
their HIV regimens. It is also possible that patients were receiving some type 
of substance use treatment while enrolled in this study, although we did not 
ask specifically about concurrent treatment. This suggests that the findings 
might not be widely generalizable to other HIV clinic populations. Another 
limitation of our study was that, although the current science on screening 
for substance use recommends using single-item screeners for clinical 
settings to determine whether further assessment is needed, we did not use 
a single-item screener to determine the presence of binge drinking. 
However, we did use a single item question to determine the need to 
administer the full ASSIST tool. As such, while we can report on moderate- or 
high-risk alcohol use, we cannot report our samples’ response to the single-
item screener, most specifically binge drinking, which is an important 
indicator for further assessment. 
Conclusions
Although there is ample evidence that PLWH report unhealthy 
substance use at higher rates than the U.S. general population and that this 
use impacts medication adherence and HIV disease progression, and can 
result in increased risks for comorbid conditions, HIV clinical settings are not 
systematically screening for or addressing substance use in HIV primary care
settings. Nurses are strategically placed to promote health and encourage 
information exchange with patients about the impact of substance use on 
their health and wellbeing. Further, patients may benefit from a clinical 
approach that includes a team-based approach to SBI in HIV primary clinics. 
Normalizing substance use screening, similar to how blood pressure is 
routinely assessed during clinic visits; assessing substance use could be a 
more integrated component of holistic care. Efforts to educate and train 
nurses in practice and as part of pre-licensure and primary care programs 
using the SBIRT model are in progress. 
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Key Considerations
 PLWH are continuing to use substances that place them at risk of poor 
health outcomes.
 Screening can be brief and still identify an individual who uses 
substances.
 Screening results could offer the nurse and patient with HIV infection an 
opportunity to discuss the risks of continued use.
 Screening begins a dialogue between nurses and PLWH regarding risk 
reduction, health promotion, and treatment outcomes.
Table 1 
Baseline Demographic Characteristics (N =168)
Variable N or M % or SD
Age (n = 163) M = 45.66 SD = 8.45
Gender
Male 115 68.4
Female (including 10 transgender 
females)
53 31.6
Race
African American/Black 68 40.5
Hispanic/Latino 27 16.1
White/Anglo (non-Hispanic) 55 32.7
Other 18 10.7
Education
High School, GED, or less 105 62.5
More than high school 63 37.5
Employed
Yes 26 15.7
No 140 84.3
Income
Totally inadequate 38 22.6
Barely adequate 103 61.3
Enough 27 16.1
Health Insurance
Yes 138 82.6
No 29 17.4
Years since HIV diagnosis (n = 
154)
M = 12.40 SD = 7.02
Viral Load < 75 copies/mL 111 66.1
CD4+ T Cell Count cells/mm3  (n 
= 152)
M = 514.74 SD = 321.86
Tobacco use previous 3 months 
(n = 167)
Yes 112 67.1
No 55 32.9
Alcohol use previous 3 months 
(n = 164)
Yes 106 64.6
No 58 35.4
Illicit substance use previous 3 months (n = 167)
Yes 134 80.2
No 33 19.8
Note. M = mean; SD = Standard Deviation; GED = Graduate Equivalency 
Diploma.
Table 2
Specific Substance Involvement Scores Stratified by Risk Level, Gender, and Race (N = 168)
Substance RiskLevel
Total
Sample
n (%)
Male
n =
115
n (%)
Female
a
n = 53
n (%)
p-
value
African
American
n = 68
n (%)
Hispani
c/
Latino
n = 27
n (%)
White/
Anglo
n = 55
n (%)
Other
n = 18
n (%)
p-
value
Tobacco Low 47
(28.0)
35
(30.4)
12
(22.6)
0.57 21 (30.9) 13
(48.2)
11
(20.0)
2
(11.1)
0.07
^
Modera
te
91
(54.2)
60
(52.2)
31
(58.5)
37 (54.4) 11
(40.7)
33
(60.0)
10
(55.6)
High 30
(17.8)
20
(17.4)
10
(18.9)
10 (14.7) 3 (11.1) 11
(20.0)
6
(33.3)
Alcoholb Low 98
(58.3)
65
(56.5)
33
(62.3)
0.47
^
40 (58.8) 17
(63.0)
32
(58.2)
9
(50.0)
0.61
^
Modera
te
52
(33.9)
39
(33.9)
18
(34.0)
25 (36.8) 7 (25.9) 19
(34.6)
6
(33.3)
High 13 (7.7) 11 (9.6) 2 (3.8) 3 (4.4) 3 (11.1) 4 (7.3) 3
(16.7)
Cannabis Low 67
(39.9)
38
(33.0)
29
(54.7)
0.03
^
33 (48.5) 13
(48.2)
13
(23.6)
8
(44.4)
0.08
^
Modera
te
88
(52.4)
68
(59.1)
20
(37.7)
30 (44.1) 12
(44.4)
38
(69.1)
8
(44.4)
High 13 (7.7) 9 (7.8) 4 (7.6) 5 (7.4) 2 (7.4) 4 (7.3) 2
(11.1)
Cocaine Low 82
(48.8)
55
(47.8)
27
(50.9)
0.97
^
27 (39.7) 20
(74.1)
24
(43.6)
11
(61.1)
0.04
^
Modera
te
66
(39.3)
46
(40.0)
20
(37.7)
33 (48.5) 4 (14.8) 23
(41.8)
6
(33.3)
High 20
(11.9)
14
(12.2)
6
(11.3)
8 (11.8) 3 (11.1) 8 (14.6) 1 (5.6)
Ampheta
mine
Low 93
(55.4)
52
(45.2)
41
(77.4)
0.00
^
51 (75.0) 13
(48.2)
22
(40.0)
7
(38.9)
0.00
^
Modera
te
57
(33.9)
46
(40.0)
11
(20.8)
16 (23.5) 11
(40.7)
22
(40.0)
8
(44.4)
High 18
(10.7)
17
(14.8)
1 (1.8) 1 (1.5) 3 (11.1) 11
(20.0)
3
(16.7)
Inhalants Low 143
(85.1)
95
(82.6)
48
(90.6)
0.48
^
60 (88.2) 23
(85.2)
44
(80.0)
16
(88.9)
0.78
^
Modera
te
24
(14.3)
19
(16.5)
5 (9.4) 8 (11.8) 4 (14.8) 10
(18.2)
2
(11.1)
High 1 (0.6) 1 (0.9) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.8) 0 (0.0)
Sedatives Low 118
(70.2)
77
(67.0)
41
(77.4)
0.48
^
53 (77.9) 17
(63.0)
34
(61.8)
14
(77.8)
0.33
^
Modera
te
45
(26.8)
34
(29.6)
11
(20.8)
14 (20.6) 8 (29.6) 19
(34.6)
4
(22.2)
High 5 (3.0) 4 (3.5) 1 (1.8) 1 (1.5) 2 (7.4) 2 (3.6) 0 (0.0)
Hallucinog
ens
Low 148
(88.1)
98
(85.2)
50
(94.3)
0.24
^
62 (91.2) 25
(92.6)
44
(80.0)
17
(94.4)
0.29
^
Modera
te
17
(10.1)
14
(12.2)
3 (5.7) 5 (7.4) 1 (3.7) 10
(18.2)
1 (5.6)
High 3 (1.8) 3 (2.6) 0 (0.0) 1 (1.5) 1 (3.7) 1 (1.8) 0 (0.0)
Opioids Low 123
(73.2)
85
(73.9)
38
(71.7)
0.54
^
55 (80.9) 22
(81.5)
32
(58.2)
14
(77.8)
0.06
^
Modera
te
38
(22.6)
24
(20.9)
14
(26.4)
11 (16.2) 3 (11.1) 20
(36.4)
4
(22.2)
High 7 (4.2) 6 (5.2) 1 (1.9) 2 (2.9) 2 (7.4) 3 (5.4) 0 (0.0)
Note. ^ indicates Fisher’s Exact test; a including 10 transgender women; b SSIS scores for Alcohol: low (0-
10), moderate (11-26), high (27+); for all other substances: low (0-3), moderate (4-26), high (27+).
Table 3
Substance Use By Urine Toxicology by Gender and Race (N =168)
Substance
Total
Sample n
(%)
Male
n = 115
n (%)
Femalea
n = 53
n (%)
p-
valu
e
African
America
n
n = 68
n (%)
Hispanic
/
Latino
n = 27
n (%)
White/
Anglo
n = 55
n (%)
Other
n = 18
n (%)
p-
valu
e
Cannabis
Absent 80 (47.
6)
52 (45.
2)
2
8 
(52.
8)
0.36 4
1 
(60.
3)
1
1 
(40.
7)
24 (43.6
)
4 (22.2
)
0.0
2^
Present 88 (52.
4)
63 (54.
8)
2
5 
(47.
2)
2
7 
(49.
7)
1
6 
(59.
3)
31 (56.4
)
1
4 
(77.8
)
Cocaine 
Absent 12
0 
(71.
4)
88 (76.
5)
3
2 
(60.
4)
0.0
3
3
8 
(55.
9)
2
2 
(81.
5)
46 (83.6
)
1
4 
(77.8
)
0.0
0^
Present 48 (28.
6)
27 (23.
5)
2
1 
(39.
6)
3
0 
(44.
1)
5 (18.
5)
9 (16.4
)
4 (22.2
)
Amphetami
ne
Absent 14
4 
(85.
7)
92 (80.
0)
5
2 
(98.
1)
0.0
0^
6
4 
(94.
1)
2
0 
(74.
1)
44 (80.0
)
1
6 
(88.9
)
0.0
3^
Present 24 (14.
3)
23 (20.
0)
1 (1.9) 4 (5.9) 7 (25.
9)
11 (20.0
)
2 (11.1
)
Methamphetamine
Absent 13
7 
(81.
6)
86 (74.
8)
5
1 
(96.
2)
0.0
0^
6
3 
(92.
6)
1
9 
(70.
4)
42 (76.4
)
1
3 
(72.2
)
0.0
1^
Present 31 (18.
4)
29 (25.
2)
2 (3.8) 5 (7.5) 8 (29.
6)
13 (23.6
)
5 (27.8
)
Benzodiaze
pines
Absent 12 (75. 90 (78. 3 (69. 0.24 5 (77. 2 (77. 38 (69.1 1 (83.3 0.60
7 6) 3) 7 8) 3 9) 1 8) ) 5 ) ^
Present 41 (24.
4)
25 (21.
7)
1
6 
(30.
2)
1
5 
(22.
1)
6 (22.
2)
17 (30.9
)
3 (16.7
)
Oxycodone
Absent 14
5 
(86.
3)
10
3 
(89.
6)
4
2
(79.
2)
0.07 5
9 
(86.
8)
2
5 
(92.
6)
43 (78.2
)
1
8 
(100.
0)
0.08
^
Present 23 (13.
7)
12 (10.
4)
1
1 
(20.
8)
9 (13.
2)
2 (7.4) 12 (21.8
)
0 (0.0)
Methadone
Absent 13
9 
(82.
7)
10
2 
(88.
7)
3
7 
(69.
8)
0.0
0^
5
7 
(83.
8)
2
3 
(85.
2)
44 (80.0
)
1
5 
(83.3
)
0.95
^
Present 29 (17.
3)
13 (11.
3)
1
6 
(30.
2)
1
1 
(16.
2)
4 (14.
8)
11 (20.0
)
3 (16.7
)
Opiates
Absent 13
6 
(81.
0)
98 (85.
2)
3
8 
(71.
7)
0.0
4
5
4 
(79.
4)
2
3 
(85.
2)
44 (80.0
)
1
5 
(83.3
)
0.96
^
Present 32 (19.
0)
17 (14.
8)
1
6 
(28.
3)
1
4 
(20.
6)
4 (14.
8)
11 (20.0
)
3 (16.7
)
Note. ^ indicates Fisher’s Exact test; a including 10 transgender women. 
